Clinical trial
PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian…
NCT00085384 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00085384 |
|---|---|
| Title | PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer |
| Official title | A Phase I/II Study to Evaluate the Optimum Dose of Pegylated-Interferon (PEG INTRON) in Patients With Platinum Resistant Ovarian, Peritoneal or Fallopian Tube Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer |
| Intervention type | Biological, Drug |
| Interventions | PEG-interferon alfa-2b |
| Enrollment | 30 |
| Start date | Jul 1, 2002 |
| Primary completion | Nov 1, 2005 |
| Completion | Apr 1, 2007 |
| First posted | Jun 11, 2004 |
| Last update posted | Aug 2, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: